In serum, first-episode, antipsychotic-nave patients show reductions in TRP, KYN, KYNA, anthranilic acid, and modestly lower 3-HK and QA, indicating early KP dysregulation, and long-term antipsychotic treatment partially normalizes these metabolites [238]
So the conceptual difference is straightforward: GLOW = GHK-Cu + BPC-157 + TB-500 (gene expression + angiogenesis + cell migration) KLOW = GHK-Cu + BPC-157 + TB-500 + KPV (adds an anti-inflammatory component) KLOW is studied when researchers want the GLOW base plus a dedicated anti-inflammatory peptide in the same formulation
In a study published in the Journal of Cutaneous and Aesthetic Surgery, the maximum dose used in one sitting was 5 g (6)
Can GHK-Cu skin serum reduce the effects of UV radiation
The difference also shows in how these molecules work with biological systems